Janux Therapeutics Inc (NASDAQ: JANX) started the day on Wednesday, with a price increase of 3.21% at $55.95, before settling in for the price of $54.21 at the close. Taking a more long-term approach, JANX posted a 52-week range of $5.65-$65.60.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 32.66%. Meanwhile, its Annual Earning per share during the time was -92.62%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 16.36%. This publicly-traded company’s shares outstanding now amounts to $46.25 million, simultaneously with a float of $41.24 million. The organization now has a market capitalization sitting at $2.92 billion. At the time of writing, stock’s 50-day Moving Average stood at $47.68, while the 200-day Moving Average is $40.26.
Janux Therapeutics Inc (JANX) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Janux Therapeutics Inc’s current insider ownership accounts for 20.95%, in contrast to 85.46% institutional ownership. According to the most recent insider trade that took place on Oct 28 ’24, this organization’s President and CEO sold 25,000 shares at the rate of 53.54, making the entire transaction reach 1,338,559 in total value, affecting insider ownership by 282,054.
Janux Therapeutics Inc (JANX) Earnings and Revenue Records
Janux Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 16.36% and is forecasted to reach -1.57 in the upcoming year.
Janux Therapeutics Inc (NASDAQ: JANX) Trading Performance Indicators
Let’s observe the current performance indicators for Janux Therapeutics Inc (JANX). It’s Quick Ratio in the last reported quarter now stands at 57.34. The Stock has managed to achieve an average true range (ATR) of 2.78. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 192.90.
In the same vein, JANX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.92, a figure that is expected to reach -0.33 in the next quarter, and analysts are predicting that it will be -1.57 at the market close of one year from today.
Technical Analysis of Janux Therapeutics Inc (JANX)
If we take a close look at the recent performances of Janux Therapeutics Inc (NASDAQ: JANX), its last 5-days Average volume was 0.64 million that shows plunge from its year to date volume of 0.71 million. During the previous 9 days, stock’s Stochastic %D was recorded 78.91% While, its Average True Range was 2.77.
Raw Stochastic average of Janux Therapeutics Inc (JANX) in the period of the previous 100 days is set at 97.28%, which indicates a major rise in contrast to 93.79% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 49.10% that was lower than 54.66% volatility it exhibited in the past 100-days period.
